News and Announcements
OncoSil Medical Appoints Charles Rowland as President
- Published December 15, 2015 1:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th December 2015, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce the appointment of Mr. Charles Rowland as President, OncoSil Medical USA.
Mr. Rowland was previously President of Sirtex Medical US from 2002 to 2006, and is a highly experienced healthcare executive with a successful record of commercialising medical devices and growing medical device companies in the diagnostics, cardiac patient management and liver cancer markets.
In his role with OncoSil Medical Mr. Rowland will be responsible for developing and executing the Company’s US Business plan and will be the Company’s official representative with the US FDA as it works towards US licensure for its lead product candidate, the OncoSilTM localiased radiation treatment for cancer.
To read the full announcement, please click here.
Company Updates
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
